Rutgers Health researchers have developed an oral antiviral drug candidate for COVID-19 that could overcome major limitations ...

Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the 12 months ended December 31, 2024, and provides updates on its antiviral product pipeline, ...

This site uses cookies to enhance your user experience. By continuing to use this site you are agreeing to our COOKIE POLICY.

David Liu, Joel Habener, and Alberto Ascherio are among recipients of this year's six Breakthrough Prizes, the "Oscars of ...

We want wide, fast, and affordable access for our new antiviral. It might sound counterintuitive, but a patent will help us ...

Stock analysts at Zacks Small Cap issued their Q1 2025 earnings per share (EPS) estimates for Cocrystal Pharma in a research ...